Research For better living

Product: Cancer immunotherapy

Cancers are recognized by the immune system, whereby costimulatory receptors expressed on T cells have proven to potently amplify anti-tumor immunity. This approach is extremely successful in treating cancer patients, applying the immune checkpoint inhibitors (ICI) PD-1 and CTLA-4.

The tumor immunology team of Triskelion combines strong scientific knowledge of oncology and immunology with pharmaceutical industry experience to develop tailor-made syngeneic and humanized xenograft models to evaluate your ICI drug candidates, such as antibodies, small molecules and vaccines.